JD HEALTH Collapses 13%+ as CLSA Says 3Q Results In Line, 4Q Growth Expected to Slow

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- JD HEALTH plummeted over 13 % in morning trading, with the stock bottoming at HKD 35.02 amid a sharp widening of losses.
- CLSA reported that the company's 3Q total revenue and adjusted EBIT rose 17 % and 14 % year-on-year to reach RMB 20 billion and RMB 1.6 billion respectively.…
Disclaimer

JD HEALTH (06618.HK) -5.800 (-14.071%) Short selling $90.55M; Ratio 21.577% opened 2.96% lower this morning (18th). With losses widening sharply in early trading, the stock bottomed at HKD35.02 and last traded at HKD35.64, down 13.54%, with turnover of HKD629 million.

CLSA said in a report that JD HEALTH's 3Q results were solid and in line. Total revenue and adjusted EBIT hiked 17% YoY and 14% YoY to RMB20 billion and RMB1.6 billion respectively. Pharmaceutical sales remained strong, up about 30% YoY, while healthcare supplements and medical device sales also improved QoQ. The broker maintained its Outperform rating and HKD61 TP.

The broker forecast JD HEALTH's 4Q total revenue growth to slow to about 11% YoY, as a milder flu season may slow pharmaceutical sales growth to 20-25% YoY, while healthcare supplement sales may rise only by LSD YoY amid weak consumer spending. The broker expected 2H total revenue and adjusted EBIT to elevate 14% YoY and 17% YoY respectively, while largely maintaining its adjusted net profit forecast unchanged.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 16:25.)

Source: AASTOCKS News The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.